Tracking how long patients stay on guselkumab for psoriatic arthritis
Part of Bones, joints & muscles, Skin clinical trials.
This study follows people with psoriatic arthritis (joint pain and swelling linked to psoriasis) who are starting a newer medication called guselkumab. Researchers want to learn how long patients continue taking this medicine and how well it works for them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with psoriatic arthritis by a rheumatologist
- You are starting guselkumab as your first, second, third, or fourth biologic treatment for psoriatic arthritis
- You have never taken another IL-23 inhibitor (a similar type of newer treatment)
- You are not taking two or more targeted arthritis drugs at the same time
- You are willing to share your health information over a long period of time
- You do not have active tuberculosis or a serious infection
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing how well guselkumab works for people with psoriatic arthritis who are starting it in everyday medical practice. Researchers want to see if the drug helps reduce joint swelling and tenderness, and if it can improve enthesitis (pain where tendons attach to bone).
This trial tests if guselkumab, a drug given as an injection under the skin, can help people with psoriatic arthritis (PsA) who haven't had enough relief from standard treatments. It aims to find a new option for managing joint pain and swelling.
This study is a long-term follow-up for children who have already finished an earlier study of guselkumab, a medicine for skin conditions like psoriasis. It looks at whether staying on the medicine continues to be safe and helpful over time.
This trial studies how guselkumab works for people with long-lasting, more severe psoriasis and signs that may affect joints. It may help by improving psoriasis symptoms and possibly reducing related inflammation, while researchers track safety and outcomes.
This study tests if guselkumab can reduce pain and inflammation in people with psoriatic arthritis. You may join if standard treatments have not worked well enough or caused side effects.
This Phase 3 study compares two biologic medicines—guselkumab and golimumab—to see which works better for people with active psoriatic arthritis. It is designed for people whose psoriatic arthritis did not respond well to a prior “TNF-blocking” medicine (or lost response).
Hear when a new Arthritis, Psoriatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.